Exhaled nitric oxide (NO) concentration is a non-invasive index for monitoring lung inflammation in diseases such as asthma. The plateau concentration at constant flow is highly dependent on the exhalation flow rate and the use of corticosteroids, and cannot distinguish airway and alveolar sources. In subjects with steroid-naïve asthma (n=8) , steroid-treated asthma (n=12), and healthy controls (n=24), we measured flowindependent NO exchange parameters, that partition exhaled NO into airway and alveolar regions, and correlated these with symptoms and lung function. The mean (SD) maximum airway flux (pl·s -1 ) and airway tissue concentration (ppb) of NO were lower in steroid-treated asthmatics compared with steroid-naïve asthmatics (1195 (836) and 143 (66) compared to 2693 (1687) and 438 (312), respectively). In contrast, the airway diffusing capacity for NO (pl·s -1 ·ppb -1 ) was elevated in both asthmatic groups compared to healthy controls independent of steroid therapy (11.8 (11.7), 8.71 (5.74) and 3.13 (1.57) for steroid-treated and steroid-naïve, and healthy controls, respectively). In addition, the airway diffusing capacity was inversely correlated with both FEV 1 and FVC (% predicted), while the airway tissue concentration was positively correlated with FVC. Consistent with previously reported results from Silkoff et. al.
INTRODUCTION
Nitric oxide (NO) was first detected in the exhaled breath of humans more than a decade ago (19) and remains a promising non-invasive index of lung pathophysiology. Substantial evidence suggests that both the airway and alveolar regions are significant sources of exhaled NO (FE NO ) (8, 20, 37, 42, 44-46, 48, 52, 53) .
Thus, in contrast to a respiratory gas like CO 2 that is evolved predominantly in the alveolar compartment and whose presence in the exhaled breath primarily reflects alveolar gas exchange, FE NO measurements might lead to specific insights about pathophysiology throughout the respiratory tract. Guidelines for characterizing FE NO by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) include only the plateau concentration in phase III, C NOplat , at a constant exhalation flow rate (3, 29) . However, a single measurement of C NOplat cannot distinguish airway and alveolar contributions, and thus may not be the optimal parameter to describe pulmonary NO exchange.
The potential for greater clinical insight is accompanied by the need for new and robust analytical approaches to characterize NO in the exhaled breath. Because NO is produced throughout the respiratory tract, factors like expiratory flow rate substantially influence the NO concentration in the exhaled breath (21, 47, 54) . To account for this and other determinants of NO concentration, we and others have described NO exchange using a biologically-relevant two-compartment model (airway and alveolar compartments) and a series of flow-independent NO exchange parameters (20, 42, 48, 52) .
The flow-independent parameters potentially provide clinically relevant information about NO exchange. For example, the alveolar NO concentration is elevated in allergic alveolitis (alveolar inflammation), while airway wall NO flux is elevated in asthma (bronchial inflammation) (37).
Inflammation is characteristic of asthma, and induces the expression of several steroid-sensitive enzymes such as nitric oxide synthase and glutaminase which impact nitric oxide metabolism (2, 23, 43) . Consequently, corticosteroids, which attenuate the inflammatory process, also reduce the concentration of nitric oxide in the exhaled breath (31, 41) . This feature of corticosteroid therapy may be useful in monitoring the inflammatory status of the airways, but, by reducing the concentration of NO in the exhaled breath to near normal, may mask steroid-independent alterations in airway NO physiology that are of potential clinical significance.
The airway diffusing capacity of NO (D awNO ) is the conductance for the transfer of NO between the airway wall and the gas stream (48, 52, 53) . It depends on both the physical features of the airway wall (e.g., airway surface area or tissue thickness) and the rate of chemical consumption (4, 53) , both of which may be altered in asthma.
METHODS
Subjects. 24 healthy adults and 20 subjects with a clinical history of asthma (8 steroidnaïve and 12 steroid-treated) participated in this study. Inclusion criteria for the healthy subjects was an FEV 1 /FVC > 0.80; exclusion criteria was a history of smoking at any time, heart disease or lung disease. Inclusion criteria for the asthma group were a clinical history of reversible bronchoconstriction, and a current FEV 1 /FVC < 0.75 regardless of the use of corticosteroids; exclusion criteria were a history of smoking at any time, heart disease, and lung disease other than asthma. We then subdivided the adults with a clinical history of asthma into 2 groups: 1) steroid-naïve and 2) steroidtreated. In addition, each of the adult subjects with asthma also completed a previously validated asthma control questionnaire (see Appendix A) to assess clinical symptoms of asthma over the past seven days (27, 28) . Subject characteristics are presented in Table 1 Table   1 ) from three consecutive maneuvers.
Airstream Analysis. A chemiluminesence NO analyzer (NOA280, Sievers, Inc., Boulder, CO) was used to measure the exhaled NO concentration. The instrument was calibrated on a daily basis using a certified NO gas (45 ppm in N 2 , Sievers, Inc., Boulder, CO). The zero point calibration was performed with a NO filter (Sievers, Inc., Boulder, CO) immediately prior to the collection of a profile. The flow rate and pressure signals were measured using a pneumotachometer (RSS100, Hans Rudolph Inc., Kansas City, MO). The pneumotachometer was calibrated daily and was set to provide the flow in units of STPD.
Data Analysis and Parameter Estimation. Experimental single exhalation profiles with
the 20-second pre-expiratory breathhold were characterized by the peak concentration in phase I and II, C NOpeak , the peak width, W 50 , in phase I and II defined as the exhaled volume in which the NO concentration was greater than 50% of C NOpeak , and the total volume of phase I and II, V I,II , defined as the inflection point (zero slope or dC exh /dV = 0) in the exhalation profile (53) (Fig. 1 ). The constant flow rate single exhalations were characterized by the plateau concentration in phase III, C NOplat , as previously described by the ATS and the ERS (3, 29).
A previously described two-compartment model was used to estimate four flowindependent NO exchange parameters: 1) maximum flux of NO from the airways, J' awNO , pl·s -1 ; 2) diffusing capacity of NO in the airways, D awNO , pl·s -1 ·ppb -1 ; 3) steady state alveolar concentration, C alv,ss , ppb; and 4) mean airway tissue NO concentration, C awNO , ppb, (equal to the ratio of J' awNO /D awNO ). A simple schematic of the twocompartment model and flow-independent parameters are presented in Fig. 2 , and a detailed description of the mathematical estimation of the parameters has been previously described (53).
The source of NO from the airways can be described by the instantaneous flux of NO from the airways, J awNO (pl/s). J awNO depends on the flow-independent parameters, and is expressed as a linear function of the airway gas phase concentration, C air , by the following:
J' awNO is the maximum flux of NO from the airway tissue equal to the product D awNO *C awNO (Eq. 2). Conceptually, J' awNO approaches J awNO as the product D awNO *C air approaches zero. D awNO is the conductance for mass transfer (transfer factor or airway diffusing capacity) of NO between the airway tissue and the gas phase. The alveolar region is characterized by the steady state alveolar gas concentration, C alv,ss , which is equivalent to the alveolar tissue concentration (25, 52) . 
V is the constant exhalation flow rate, and C* NOplat is the plateau concentration of NO predicted by the model using the flow-independent parameters. We have previously demonstrated that C* NOplat is not different than the experimentally measured C NOplat in healthy adults (44, 53) , with the advantage that inter-subject and inter-population variations in flow rate can be accounted for by calculating C NOplat at a precise desired flow rate (e.g., 50 ml/s).
Statistics. To detect differences among the three groups of subjects, data were analyzed using One-way Analysis of Variance (ANOVA) and post-hoc paired comparisons of treatment means. In those instances where Levene's test rejected homogeneity of variance, tests for group differences relied upon Welch's ANOVA or Satterthwaite's method to adjust the test to account for this problem. To detect significant relationships between the parameters which characterize nitric oxide exchange and either asthma symptoms or standard indices of lung function (e.g., FEV1), we utilized first and second order partial correlation coefficients, respectively.
For example, to determine the relationship between NO parameters and lung function for all subjects, the second order partial correlation coefficient factors out the effect of having asthma or being treated with steroids by subtracting the group mean from each individual score. As to the question of Normality, in addition to screening variables for excessive skewness, all tests of group differences were rerun using a log transformation of the dependent variables. Because the log transformation of each variable did not impact the results, all statistical tests were reported using the untransformed data. Finally, a p-value < 0.05 was considered statistically significant, and all results were produced using the GLM procedure of SAS.
RESULTS
FVC, FEV 1 , FEV 1 /FVC, and the clinical history of the subjects with asthma are presented in Table 1 . FEV 1 /FVC was more reproducible that FEV 1 alone. The mean maximum variability (defined as the difference between the maximum and minimum value normalized by the mean of the three repeated maneuvers) for FEV 1 /FVC was 5.8% (range 1.5-10.2) and 2.9% (range 0-10.2) for steroid-naïve and steroid-treated asthma subjects, respectively. For FEV 1 alone, the mean maximum variability was slightly higher for each group --8.9% (range 0.7-20.6) and 5.2% (range 1.5-17.9) for steroid-naïve and steroid-treated asthma subjects, respectively. FEV 1 /FVC was significantly lower in both groups of subjects with asthma compared to healthy adults.
However, there was no difference in FEV 1 /FVC or clinical symptoms (as assessed by the composite score on the asthma control questionnaire) among the two groups of subjects with asthma.
Of the 20 subjects with asthma, three of the steroid-treated (subject #2, #10 and #12) were not able to complete the 20-second breathhold, and thus we utilized a 10second breathhold which may increase the confidence interval of D awNO (44, 53) . To highlight differences amongst groups in exhaled concentrations, a composite exhalation profile for each group was attained ( Fig. 4A and 4B ) by taking the mean exhaled concentration at equivalent exhaled volume intervals for each of the three groups. The three asthmatic subjects who were not able to complete the 20-second breathhold were excluded from the composite exhalation profile. Steroid-naïve subjects with asthma had an increased concentration of NO in all phases of the exhalation profile when compared to both steroid-treated subjects with asthma and healthy controls. Although the NO exhalation profile for steroid-treated subjects with asthma and healthy controls is similar ( Fig. 4B ), there are important differences that reflect alterations in the flow-independent NO parameters. Steroid-treated subjects with asthma have elevated NO in phase III that is reflected in a steeper phase III slope.
This steeper slope reflects a greater airway wall flux (J' awNO ) as opposed to an elevated alveolar concentration (C alv,ss ) which would cause a uniform increase in NO concentration over phase III (52, 53). The elevated J' awNO would result in a much larger C NOpeak than actually observed, and this results in an elevated D awNO as described below.
Mean (SD) C NOpeak for steroid-naïve, steroid-treated, and healthy subjects were 192 (127) ppb, 82 (42) ppb, and 67 (29) ppb, respectively. C NOpeak for steroid-naïve subjects with asthma was statistically larger than the other two groups. Mean (SD) W 50 for steroid-naïve, steroid-treated, and healthy subjects were 189 (60), 171 (49), and 190 (51) ml, and were not different amongst groups. Mean (SD) V I,II for steroid-naïve, steroid-treated, and healthy subjects were 657 (98), 604 (127), and 668 (142) ml, and were also not different amongst the groups.
As shown in Fig. 5 , J' awNO and D awNO , are elevated in steroid-naïve subjects with asthma relative to healthy controls. The use of corticosteroids does not impact D awNO , but is associated with a significantly lower J' awNO and C awNO that are equivalent to healthy adults. C alv,ss is not different amongst the three groups.
The experimental values of C NOplat at the target flow rates of 50 ml/s and 250 ml/s, respectively are presented in Table 2 (A: healthy adults and B: subjects with asthma) along with the model-predicted C NOplat (Eq. 3, C* NOplat ) at exhalation flow rates of exactly 50 ml/s and 250 ml/s. C* NOplat and C NOplat were not statistically different from each other with the exception of the steroid naïve group of asthmatic subjects at 250 ml/s (see Table 2B ). Statistical differences between the groups did not depend on the choice of C NOplat or C* NOplat . Thus, to control for small variations in the exhalation flow rate between groups (e.g., mean exhalation flow rate at the target of 50 ml/s was 62 ml/s and 55 ml/s for steroid-naïve and steroid-treated groups, respectively), statistical differences between groups are presented using C* NOplat ( 
DISCUSSION
In the current study, we estimate flow-independent NO exchange parameters with a single exhalation breathing technique, and plateau exhaled NO concentrations following ATS and ERS guidelines in a group of subjects with a low FEV 1 (FEV 1 /FVC < 0.75) and a clinical history of asthma. We found that the use of corticosteroids was associated with a decrease in the plateau exhaled NO concentrations at flow rates of 50 ml/s and 250 ml/s as well as a decrease in the flow-independent parameters that reflect airway tissue concentration (J' awNO and C awNO ), respectively. In contrast, D awNO was elevated in both groups of asthmatic subjects, and was independent of the use of corticosteroids. These findings are in good agreement with previously published data by Silkoff et al (48) despite using a different breathing maneuver and analytical technique to estimate the flow-independent NO exchange parameters. In addition, we found that D awNO is inversely correlated with both FEV 1 and FVC (% predicted) independent of the presence of asthma and steroid use. Thus, we confirm that D awNO may reflect physiological changes in the lungs that impact lung function independent of the use of corticosteroids.
Since the initial reports that FE NO in asthma was elevated (1, 30) , subsequent studies have focused on exploring the correlation between exhaled NO concentration and other inflammatory markers (i.e., eosinophils), clinical interventions such as corticosteroids, and standard indices of lung function (i.e., FEV 1 /FVC). Corticosteroid treatment significantly decreases C NOplat in subjects with asthma (31, 40, 41), and the dose of steroid is inversely related to C NOplat (32). In addition, an increase in C NOplat has recently been shown to be equally effective as sputum eosinophils and airway hyperresponsiveness to hypertonic saline as a predictor for loss of asthma control (26) .
However, the current study as well as that of Silkoff et.al. (48) demonstrate the presence of steroid-independent factors (i.e., D awNO ) that can also contribute to the elevated levels of NO in the exhaled breath of asthmatics.
We are also now aware of disease states in which exhaled concentration of NO is in the normal range only because abnormalities in the flow-independent determinants of NO concentration balance each other. For example, in scleroderma, the alveolar concentration of NO is elevated while the airway wall flux of NO is reduced (15) . In cystic fibrosis, the airway diffusing capacity of NO (transfer factor) is elevated, but the airway wall concentration is reduced leading to an exhaled NO concentration that is similar to healthy controls (45). Although we utilized a different breathing maneuver and technique to estimate the flowindependent NO parameters, our results are consistent with previously reported trends (22, 38, 48) , and also demonstrates that D awNO is inversely correlated with FEV 1 and FVC (% predicted) and C awNO is positively correlated with FVC. The positive correlation of C awNO with FVC is likely due to the fact that it is inversely related to D awNO (i.e., C awNO = J' awNO /D awNO ). Of note is the fact that Silkoff et al. (48) reported that values of J' awNO , D awNO , and C awNO after steroid use in asthmatic subjects were all positively correlated with FEV 1 /FVC (% predicted). These important differences may be due to differences in study design and the technique used to estimate the flowindependent NO parameters. Nonetheless, future studies will need to continue to investigate the relationship between NO flow-independent parameters and lung function.
Exhaled nitric oxide concentration necessarily reflects both the chemical and physical properties of the airway wall and alveoli as well as the endogenous production rate from nitric oxide synthase (NOS) isoforms in the airway and alveoli. Our ability to estimate the flow-independent NO parameters, which depend on these properties from the exhaled concentration signal, can be illustrated using the composite exhalation profile (Fig. 4A) . We have previously demonstrated that only phase I and II are sensitive to changes in D awNO (if D awNO increases, less NO is exhaled in phase I and II), only phase III is sensitive to C alv,ss (if C alv,ss increases, there is a uniform increase across exhaled volume in phase III), and all three phases are sensitive to J' awNO (if J' awNO increases, there is more NO exhaled in all phases, and the impact on phase III is a steeper slope) (53) (see Fig. 3 ). Thus, the observed changes in the composite profile of each group are consistent with our reported values of the flow-independent parameters. For example, steroid-treated subjects with asthma have a steeper slope in phase III and a higher concentration (necessitating a larger J' awNO ), yet a similar amount of NO in phase I and II (necessitating a larger D awNO to balance the increased J' awNO ). Of note is the fact that amongst the parameters characterizing phase I and II of the exhalation profile, only C NOpeak differs between the groups (W 50 and V I,II are not different between the three groups). This is consistent with altered NO production and transport in the airway wall during the breathhold, but also suggests that the volume accumulating NO during the breathhold and subsequently eliminated during exhalation is similar between the three groups.
We have previously reported analytical expressions for the flow-independent parameters that approximate the functional dependence on the surface area emitting nitric oxide (A i , cm 2 , where subscript "i" refers to the airways, "aw", or the alveoli, "alv"), D awNO is independent of S awNO , is a positive function of A aw , t:air , D t,NO , and k, and is an inverse function of L t,aw (Eq. B2 in Appendix B). Thus, the increase in D awNO may be due to alterations in any of these parameters. The airway wall in asthma is generally considered to be thicker than in healthy controls due to remodeling processes such as subepithelial fibrosis and increased mucous production (56) . The thicker airway wall would tend to increase the diffusion distance for NO, and the mucous tends to be more viscous which would decrease the "ease" at which NO can diffuse (i.e., decrease D t,NO ) (4). Both of these observations would decrease D awNO and contrast with our experimental observation, as well as that of Silkoff et. al (48) , of an elevated D awNO . Enhanced chemical consumption, primarily with superoxide (9), can increase D awNO due to an increase in the radial concentration gradient (4, 45) .
However, D awNO remains elevated following steroid treatment, which has been reported to suppress superoxide release (10) .
An increase in A aw is a plausible mechanism for the increase in D awNO . Silkoff et.
al (48) postulated that extension of the nitric oxide producing non-adrenergic noncholinergic (NANC) nerves from the large airways into the small airways may increase the surface area emitting nitric oxide, which is supported both directly and indirectly by several studies (6, 7, 16, 17, 39, 55) . Expression of iNOS in the airways of subjects with asthma has been demonstrated (12, 36, 50) which could potentially increase A aw ; however, this possible mechanism would likely be sensitive to corticosteroid therapy which is not the observation. (18), nitrite reduction to NO at lower pH (23, 24, 35) , and GSNO catabolism (5, 11, 14, 49) could also increase S awNO , and contribute to the increase in J' awNO for steroid-naïve subjects with asthma.
Steroid treatment dramatically decreases the exhaled NO concentration (see Fig   5) , which corresponds to observed decreases in J' awNO and C awNO as well as C NOplat at both 50 ml/s and 250 ml/s flow rates. As previously discussed, steroid therapy decreases superoxide production which would correspond to a reduced consumption rate and an increase in J' awNO , which is not observed. The decrease in J' awNO in steroid- 
APPENDIX A: Asthma Control Questionnaire
The following six questions are from a previously published and validated asthma control questionnaire (27, 28). Each question is answered by the subject on a scale of 0 to 6 representing the absence (score of 0) to severe (score of 6) symptoms. The composite score is then the mean of the six scores. Thus, a higher composite score reflects more asthmatic symptoms. The questionnaire has been shown to have improved discriminative and evaluative measurement properties than an asthma control diary (27).
APPENDIX B: Mathematical description of flow-independent NO parameters
The following analytical expressions for the steady state values of J' awNO , D awNO and C alv,ss have been previously derived (52) and presented in a slightly different form (45, 
